» Articles » PMID: 37274211

Dominant Aminoacyl-tRNA Synthetase Disorders: Lessons Learned from Disease Models

Overview
Journal Front Neurosci
Date 2023 Jun 5
PMID 37274211
Authors
Affiliations
Soon will be listed here.
Abstract

Aminoacyl-tRNA synthetases (ARSs) play an essential role in protein synthesis, being responsible for ligating tRNA molecules to their corresponding amino acids in a reaction known as 'tRNA aminoacylation'. Separate ARSs carry out the aminoacylation reaction in the cytosol and in mitochondria, and mutations in almost all ARS genes cause pathophysiology most evident in the nervous system. Dominant mutations in multiple cytosolic ARSs have been linked to forms of peripheral neuropathy including Charcot-Marie-Tooth disease, distal hereditary motor neuropathy, and spinal muscular atrophy. This review provides an overview of approaches that have been employed to model each of these diseases , followed by a discussion of the existing animal models of dominant ARS disorders and key mechanistic insights that they have provided. In summary, ARS disease models have demonstrated that loss of canonical ARS function alone cannot fully account for the observed disease phenotypes, and that pathogenic ARS variants cause developmental defects within the peripheral nervous system, despite a typically later onset of disease in humans. In addition, aberrant interactions between mutant ARSs and other proteins have been shown to contribute to the disease phenotypes. These findings provide a strong foundation for future research into this group of diseases, providing methodological guidance for studies on ARS disorders that currently lack models, as well as identifying candidate therapeutic targets.

Citing Articles

Piggyback knockdown screening of unique genes of zebrafish young thrombocytes identifies eight novel genes in thrombopoiesis.

Fallatah W, Mary J, Dhinoja S, Vallabhaneni S, Jagadeeswaran P Sci Rep. 2025; 15(1):5180.

PMID: 39939668 PMC: 11822207. DOI: 10.1038/s41598-025-88866-9.


A model organism pipeline provides insight into the clinical heterogeneity of TARS1 loss-of-function variants.

Meyer-Schuman R, Cale A, Pierluissi J, Jonatzke K, Park Y, Lenk G HGG Adv. 2024; 5(3):100324.

PMID: 38956874 PMC: 11284558. DOI: 10.1016/j.xhgg.2024.100324.

References
1.
Gutmann L, Shy M . Update on Charcot-Marie-Tooth disease. Curr Opin Neurol. 2015; 28(5):462-7. DOI: 10.1097/WCO.0000000000000237. View

2.
Gillespie M, McMillan H, Kernohan K, Pena I, Meyer-Schuman R, Antonellis A . A Novel Mutation in MARS in a Patient with Charcot-Marie-Tooth Disease, Axonal, Type 2U with Congenital Onset. J Neuromuscul Dis. 2019; 6(3):333-339. PMC: 6889022. DOI: 10.3233/JND-190404. View

3.
Frohlich D, Mendes M, Kueh A, Bongers A, Herold M, Salomons G . A Hypomorphic Model Recapitulates Key Aspects of the Leukodystrophy HBSL. Front Cell Neurosci. 2021; 14:625879. PMC: 7855723. DOI: 10.3389/fncel.2020.625879. View

4.
Rips J, Meyer-Schuman R, Breuer O, Tsabari R, Shaag A, Revel-Vilk S . MARS variant associated with both recessive interstitial lung and liver disease and dominant Charcot-Marie-Tooth disease. Eur J Med Genet. 2018; 61(10):616-620. PMC: 6133759. DOI: 10.1016/j.ejmg.2018.04.005. View

5.
Rohkamm B, Reilly M, Lochmuller H, Schlotter-Weigel B, Barisic N, Schols L . Further evidence for genetic heterogeneity of distal HMN type V, CMT2 with predominant hand involvement and Silver syndrome. J Neurol Sci. 2007; 263(1-2):100-6. PMC: 3272403. DOI: 10.1016/j.jns.2007.06.047. View